Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

To Explore the Mechanism of the GRM4 Gene in Osteosarcoma by RNA Sequencing and Bioinformatics Approach.

Pang Y, Zhao J, Fowdur M, Liu Y, Wu H, He M.

Med Sci Monit Basic Res. 2018 Jan 17;24:16-25.

2.

Analysis of positive and negative allosteric modulation in metabotropic glutamate receptors 4 and 5 with a dual ligand.

Dalton JAR, Pin JP, Giraldo J.

Sci Rep. 2017 Jul 10;7(1):4944. doi: 10.1038/s41598-017-05095-5.

3.

Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Lindsley CW, Emmitte KA, Hopkins CR, Bridges TM, Gregory KJ, Niswender CM, Conn PJ.

Chem Rev. 2016 Jun 8;116(11):6707-41. doi: 10.1021/acs.chemrev.5b00656. Epub 2016 Feb 16. Review.

4.

Expression of metabotropic glutamate receptor 4 in osteosarcoma.

Wang S, Wei X, Chen B, Zhao M, Song G, Zhang Z, Li N.

Mol Clin Oncol. 2016 Jan;4(1):65-69. Epub 2015 Oct 23.

5.

mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.

Morin N, Morissette M, Grégoire L, Di Paolo T.

Curr Neuropharmacol. 2016;14(5):481-93. Review.

6.

Glutamatergic transmission in drug reward: implications for drug addiction.

D'Souza MS.

Front Neurosci. 2015 Nov 5;9:404. doi: 10.3389/fnins.2015.00404. eCollection 2015. Review.

7.

Functional modulation of G-protein coupled receptors during Parkinson disease-like neurodegeneration.

Jenkins BG, Zhu A, Poutiainen P, Choi JK, Kil KE, Zhang Z, Kuruppu D, Aytan N, Dedeoglu A, Brownell AL.

Neuropharmacology. 2016 Sep;108:462-73. doi: 10.1016/j.neuropharm.2015.11.010. Epub 2015 Nov 12.

8.

Selective Negative Allosteric Modulation Of Metabotropic Glutamate Receptors – A Structural Perspective of Ligands and Mutants.

Harpsøe K, Isberg V, Tehan BG, Weiss D, Arsova A, Marshall FH, Bräuner-Osborne H, Gloriam DE.

Sci Rep. 2015 Sep 11;5:13869. doi: 10.1038/srep13869.

9.

Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Sengmany K, Gregory KJ.

Br J Pharmacol. 2016 Oct;173(20):3001-17. doi: 10.1111/bph.13281. Epub 2015 Nov 11. Review.

10.

A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude).

Hammer H, Bader BM, Ehnert C, Bundgaard C, Bunch L, Hoestgaard-Jensen K, Schroeder OH, Bastlund JF, Gramowski-Voß A, Jensen AA.

Mol Pharmacol. 2015 Aug;88(2):401-20. doi: 10.1124/mol.115.099291. Epub 2015 Jun 8.

11.

Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation.

Gregory KJ, Conn PJ.

Mol Pharmacol. 2015 Jul;88(1):188-202. doi: 10.1124/mol.114.097220. Epub 2015 Mar 25.

12.

Determinants of endogenous ligand specificity divergence among metabotropic glutamate receptors.

Kang HJ, Wilkins AD, Lichtarge O, Wensel TG.

J Biol Chem. 2015 Jan 30;290(5):2870-8. doi: 10.1074/jbc.M114.622233. Epub 2014 Dec 17.

13.

Inhibition of metabotropic glutamate receptor 5 induces cellular stress through pertussis toxin-sensitive Gi-proteins in murine BV-2 microglia cells.

Chantong B, Kratschmar DV, Lister A, Odermatt A.

J Neuroinflammation. 2014 Nov 19;11:190. doi: 10.1186/s12974-014-0190-7.

14.

The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators.

Br J Pharmacol. 2013 Dec;170(8):1459-581. doi: 10.1111/bph.12445.

15.

A novel mGluR5 antagonist, MFZ 10-7, inhibits cocaine-taking and cocaine-seeking behavior in rats.

Keck TM, Zou MF, Bi GH, Zhang HY, Wang XF, Yang HJ, Srivastava R, Gardner EL, Xi ZX, Newman AH.

Addict Biol. 2014 Mar;19(2):195-209. doi: 10.1111/adb.12086. Epub 2013 Sep 4.

16.

Metabotropic glutamate receptors for Parkinson's disease therapy.

Gasparini F, Di Paolo T, Gomez-Mancilla B.

Parkinsons Dis. 2013;2013:196028. doi: 10.1155/2013/196028. Epub 2013 Jun 19.

17.

Fenobam sulfate inhibits cocaine-taking and cocaine-seeking behavior in rats: implications for addiction treatment in humans.

Keck TM, Yang HJ, Bi GH, Huang Y, Zhang HY, Srivastava R, Gardner EL, Newman AH, Xi ZX.

Psychopharmacology (Berl). 2013 Sep;229(2):253-65. doi: 10.1007/s00213-013-3106-9. Epub 2013 Apr 25.

18.

Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.

Robichaud AJ, Engers DW, Lindsley CW, Hopkins CR.

ACS Chem Neurosci. 2011 Aug 17;2(8):433-49. doi: 10.1021/cn200043e. Epub 2011 Jun 14. Review.

19.

Potentiation of mGlu5 receptors with the novel enhancer, VU0360172, reduces spontaneous absence seizures in WAG/Rij rats.

D'Amore V, Santolini I, van Rijn CM, Biagioni F, Molinaro G, Prete A, Conn PJ, Lindsley CW, Zhou Y, Vinson PN, Rodriguez AL, Jones CK, Stauffer SR, Nicoletti F, van Luijtelaar G, Ngomba RT.

Neuropharmacology. 2013 Mar;66:330-8. doi: 10.1016/j.neuropharm.2012.05.044. Epub 2012 Jun 15.

20.

Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators.

Mueller R, Dawson ES, Niswender CM, Butkiewicz M, Hopkins CR, Weaver CD, Lindsley CW, Conn PJ, Meiler J.

J Mol Model. 2012 Sep;18(9):4437-46. doi: 10.1007/s00894-012-1441-0. Epub 2012 May 17.

Supplemental Content

Support Center